Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FULC Fulcrum Therapeutics	$6.85 +1.0%	$5.23	$2.32 ▼ $10.13	$369.76M	2.41	965,833 shs	247,184 shs
HUMA Humacyte	$2.37 -1.7%	$1.91	$1.15 ▼ $9.79	$367.63M	2	3.87 million shs	2.72 million shs
IOBT IO Biotech	$1.35 -10.0%	$1.10	$0.66 ▼ $1.73	$88.94M	0.36	282,949 shs	383,060 shs
KMDA Kamada	$6.88 -0.9%	$6.65	$4.74 ▼ $9.16	$395.63M	0.94	93,860 shs	109,223 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FULC Fulcrum Therapeutics	0.00%	-5.52%	+3.79%	+119.55%	-11.15%
HUMA Humacyte	0.00%	-8.49%	+25.40%	-22.04%	-67.71%
IOBT IO Biotech	0.00%	-15.63%	+32.35%	+53.62%	+5.47%
KMDA Kamada	0.00%	+0.44%	+0.29%	-4.18%	+34.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FULC Fulcrum Therapeutics	0.4219 of 5 stars	1.3	0.0	2.8	2.5	0.0
HUMA Humacyte	2.3174 of 5 stars	3.5	1.0	2.6	2.5	0.6
IOBT IO Biotech	3.822 of 5 stars	3.7	5.0	2.7	2.5	1.3
KMDA Kamada	3.8728 of 5 stars	3.4	3.0	2.9	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FULC Fulcrum Therapeutics	2.50	Moderate Buy	$6.29	-8.24% Downside
HUMA Humacyte	3.00	Buy	$11.71	394.27% Upside
IOBT IO Biotech	3.33	Buy	$9.33	591.36% Upside
KMDA Kamada	2.75	Moderate Buy	$14.67	113.18% Upside

Current Analyst Ratings Breakdown

Latest IOBT, HUMA, KMDA, and FULC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00
5/15/2025	FULC Fulcrum Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$10.00
5/15/2025	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
5/14/2025	IOBT IO Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/14/2025	HUMA Humacyte	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
5/14/2025	HUMA Humacyte	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $14.00
5/13/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
5/8/2025	KMDA Kamada	Sidoti Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FULC Fulcrum Therapeutics	$80M	4.62	N/A	N/A	$3.80 per share	1.80
HUMA Humacyte	$517K	711.09	N/A	N/A	$0.13 per share	18.23
IOBT IO Biotech	N/A	N/A	N/A	N/A	$2.02 per share	N/A
KMDA Kamada	$167.24M	2.37	$0.38 per share	17.90	$4.25 per share	1.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FULC Fulcrum Therapeutics	-$97.33M	-$0.07	N/A	N/A	N/A	N/A	-7.31%	-6.74%	7/30/2025 (Estimated)
HUMA Humacyte	-$110.78M	-$0.69	N/A	N/A	N/A	N/A	-942.81%	-93.82%	8/12/2025 (Estimated)
IOBT IO Biotech	-$86.08M	-$1.37	N/A	N/A	N/A	N/A	-86.56%	-75.24%	8/12/2025 (Estimated)
KMDA Kamada	$8.28M	$0.29	24.57	21.50	0.97	9.92%	6.30%	4.49%	8/13/2025 (Estimated)

Latest IOBT, HUMA, KMDA, and FULC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	KMDA Kamada	$0.07	$0.07	N/A	$0.07	$154.06 million	$44.02 million
5/13/2025	Q1 2025	HUMA Humacyte	-$0.19	-$0.10	+$0.09	$0.28	$0.46 million	$0.52 million
5/1/2025	Q1 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A
3/28/2025	Q4 2024	HUMA Humacyte	-$0.23	-$0.16	+$0.07	-$0.16	$0.64 million	$7.23 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
IOBT IO Biotech	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FULC Fulcrum Therapeutics	N/A	18.44	18.44
HUMA Humacyte	N/A	1.10	1.10
IOBT IO Biotech	N/A	5.37	5.37
KMDA Kamada	N/A	4.84	2.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FULC Fulcrum Therapeutics	89.83%
HUMA Humacyte	44.71%
IOBT IO Biotech	54.76%
KMDA Kamada	20.38%

Insider Ownership

Company	Insider Ownership
FULC Fulcrum Therapeutics	7.00%
HUMA Humacyte	5.10%
IOBT IO Biotech	4.80%
KMDA Kamada	36.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FULC Fulcrum Therapeutics	100	53.98 million	51.73 million	Optionable
HUMA Humacyte	150	155.12 million	111.76 million	Optionable
IOBT IO Biotech	30	65.88 million	64.37 million	Not Optionable
KMDA Kamada	360	57.51 million	36.73 million	Optionable

IOBT, HUMA, KMDA, and FULC Headlines

Recent News About These Companies

Daichi Kamada Highlights Quality Gap Between Indonesian and Australian National Teams

June 12 at 11:52 AM | en.tempo.co

Kamada nets brace in Japan rout as South Korea put four past Kuwait

June 10, 2025 | beinsports.com

Kamada hits double as Japan thrash Indonesia 6-0

June 10, 2025 | msn.com

Implied Volatility Surging for Kamada Stock Options

June 10, 2025 | msn.com

Football: Daichi Kamada, Takefusa Kubo spur Japan to big win over Indonesia

June 10, 2025 | mainichi.jp

Millennium Management LLC Sells 36,872 Shares of Kamada Ltd. (NASDAQ:KMDA)

June 3, 2025 | marketbeat.com

Wall Street Analysts Think Kamada (KMDA) Could Surge 106.86%: Read This Before Placing a Bet

June 2, 2025 | zacks.com

Are Investors Undervaluing Kamada (KMDA) Right Now?

June 2, 2025 | zacks.com

KMDA vs. CSLLY: Which Stock Should Value Investors Buy Now?

May 28, 2025 | zacks.com

Kamada (NASDAQ:KMDA) Stock Crosses Below 200 Day Moving Average - What's Next?

May 28, 2025 | marketbeat.com

HC Wainwright Issues Optimistic Outlook for Kamada Earnings

May 20, 2025 | marketbeat.com

Is Kamada (KMDA) Stock Undervalued Right Now?

May 16, 2025 | msn.com

Wall Street Analysts Believe Kamada (KMDA) Could Rally 106.56%: Here's is How to Trade

May 16, 2025 | msn.com

Compared to Estimates, Kamada (KMDA) Q1 Earnings: A Look at Key Metrics

May 15, 2025 | msn.com

Kamada Ltd (KMDA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion

May 15, 2025 | finance.yahoo.com

Kamada Ltd. (NASDAQ:KMDA) Q1 2025 Earnings Call Transcript

May 15, 2025 | msn.com

Kamada Ltd. (KMDA) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

Kamada (KMDA) Q1 Earnings Match Estimates

May 14, 2025 | zacks.com

Kamada Reports Strong Q1 2025 Financial Results and Expands Plasma Operations

May 14, 2025 | tipranks.com

Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability

May 14, 2025 | globenewswire.com

Earnings Preview For Kamada

May 14, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOBT, HUMA, KMDA, and FULC Company Descriptions

Fulcrum Therapeutics NASDAQ:FULC

$6.85 +0.07 (+1.03%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$6.82 -0.03 (-0.50%)

As of 06/13/2025 04:47 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Humacyte NASDAQ:HUMA

$2.37 -0.04 (-1.66%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.38 +0.00 (+0.21%)

As of 06/13/2025 07:54 PM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

IO Biotech NASDAQ:IOBT

$1.35 -0.15 (-10.00%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.34 -0.02 (-1.11%)

As of 06/13/2025 07:21 PM Eastern

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Kamada NASDAQ:KMDA

$6.88 -0.06 (-0.86%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$6.94 +0.05 (+0.80%)

As of 06/13/2025 04:25 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time